Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 8/20 | 0.40 |
| ▸ | BCL2 | P10415 | 7/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6502208 | 0.92 | MCL1 (0.44) | MCL1BCL2PPARGALOX5AP | |
| SCHEMBL6490840 | 0.91 | BCL2 (0.46) | MCL1BCL2PPARGALDH1A1GAA | |
| SCHEMBL6500385 | 0.91 | PPARG (0.45) | MCL1BCL2PPARGALDH1A1LMNA | |
| SCHEMBL6496934 | 0.87 | MCL1 (0.54) | MCL1BCL2 | |
| SCHEMBL7194322 | 0.86 | BCL2 (0.48) | MCL1BCL2 | |
| SCHEMBL6487942 | 0.85 | MCL1 (0.42) | MCL1PPARGGAA | |
| SCHEMBL6489090 | 0.84 | PPARG (0.43) | PPARGLMNAL3MBTL1 | |
| SCHEMBL6500949 | 0.84 | BCL2 (0.54) | MCL1BCL2 | |
| SCHEMBL6489066 | 0.83 | PPARG (0.37) | MCL1BCL2PPARGLMNAALOX5AP | |
| SCHEMBL6489570 | 0.83 | BCL2 (0.46) | MCL1BCL2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | MCL1 806/4885BCL2 774/4885PPARG 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.